All rights reserved. Charles St, Baltimore, MD The vaccine is currently in a Phase 3 trial which is supposed to determine its effectiveness as a treatment for cervical cancer that is triggered by HPV.
Department of Defense. Inovio was founded inand Kim has been its CEO since Yet the company does not appear to have any products on the market. Inovio Biomedical later became Inovio Pharmaceuticals. But aside from that all-stock transaction, Kim has apparently never sold a company. Importantly, Inovio said that it had developed its Covid vaccine in three hours. Still, the fact that it developed the product in just three hours makes me less confident in its effectiveness.
That amount of money represents a huge vote of confidence in Moderna and its technology. But the only positive data it reported on its website came from the trial of VGX, for the prevention of cervical cancer.
But it, like Moderna, is competing with much larger companies that are also trying to develop a vaccine for the virus. Finally, its leaders have more impressive backgrounds than Kim. The valuations of both Moderna and Inovio are steep at this point. Larry Ramer has conducted research and written articles on U. Larry began writing columns for InvestorPlace in Among his highly successful, contrarian picks have been GE, solar stocks and Snap.
You can reach him on StockTwits at larryramer. As of this writing, he did not own any shares of the aforementioned companies. Premium Services Newsletters. Sign out. About Us Our Analysts. Register Here Free. Compare Brokers.The company, based in Plymouth Meeting, Pa. Inovio did not respond to phone calls and emails seeking comment. Joseph Kim said that the company aims to test its vaccine in the U. And we are working with different manufacturers to scale up as we need.
So far, 1, people have died from the diseaseaccording to the World Health Organization. The U. Founded in the early s, Inovio develops DNA-based treatments for cancer and infectious diseases. Its proprietary platform triggers potent immune responses in the body to fight certain viruses and cancers. Its mission is to develop vaccines to stop future epidemics. Gilead Sciences of Foster City, which makes anti-HIV drugs, announced that it will conduct trials related to its existing treatments.
In both cases, the companies are testing existing drugs currently on the market, albeit to treat different diseases. There are a host of smaller biotech companies like Inovio that are also trying to develop a vaccine, though the extent of their efforts remains unclear.
France announces first death of coronavirus patient outside Asia. Inovio has worked on vaccines for health emergencies before, including programs for Ebola and the Zika outbreaks about five years ago. While the company is still pursuing both vaccines, they remain in clinical trials and have not yet come to market.
Meanwhile, vaccines for Ebola have been made available from other companies in certain countries in Africa. As of Aprilno Zika vaccine had been approved. For the COVID coronavirusInovio said it is establishing a coalition of partners and a financial backer to push ahead with pre-clinical development and Phase 1 human clinical testing in the U.
At the same time, it is working with Beijing Advaccine Biotechnology Co. Get our Boiling Point newsletter for the latest on the power sector, water wars and more — and what they mean for California. You may occasionally receive promotional content from the Los Angeles Times.The biotech's push to develop a vaccine against the novel coronavirus, COVID, in record time has sparked an avalanche of interest in its stock.
One of the big reasons is that Inovio announced last week that researchers at its San Diego facility were able to construct a vaccine for COVID in just a matter of hours after gaining access to the virus' genetic sequence. The company thus hopes to begin human trials for the experimental vaccine as soon as this summeraccording to a recent interview with CEO J.
Joseph Kim. What's the big deal? COVID has already spread to 29 countries, caused over 1, fatalities in mainland China, and effectively shut down some major global supply chains.Inovio Inc. Says That Its Experimental Vaccine Showed Potential To Prevent COVID-19
What's more, this deadly respiratory disease exhibits several traits such as an extensive incubation phase that may result in its becoming endemic, similar to seasonal outbreaks of the flu. In other words, COVID may not simply evaporate for the most part like other severe coronavirus strains, such as the Middle East respiratory syndrome.
In that event, a vaccine or an antiviral therapy will be absolutely essential in the battle against this highly infectious, and sometimes fatal, respiratory ailment. Should investors pounce on Inovio's shares in response to this viral threat? Let's take a closer look at the bull and bear cases for this biotech stock to find out.
If COVID evolves into an endemic respiratory disease, the commercial opportunity could be quite staggering. Now, COVID will likely never morph into that kind of behemoth market, but it could very well end up supporting one or more vaccines that generate several hundred million in annual sales, especially if it becomes a serious problem in affluent western nations like the United States.
So, in a sense, there is a solid rationale supporting Inovio's The bad news is that Inovio has never actually developed a commercial-stage vaccine. Despite being in business for 40 yearsthe company is only now on the cusp of generating late-stage data for one of its DNA-based therapies.
Another worrying sign is that this isn't the first time Inovio's stock has skyrocketed in response to an infectious disease threat. Infor instance, the biotech's shares took flight after it announced plans to tackle the Zika virus. Per the company's latest clinical update in earlyhowever, its Zika virus product candidate hasn't even made it past a phase 1 trial yet. If your sole purpose is to own a company likely to benefit from the COVID threat, Inovio probably isn't your best bet.
The company has never brought a product to market in four decades, much to the detriment of long-suffering shareholders. Since going public, in fact, Inovio's stock has produced a negative return on capital of Perhaps this story will change for the better with a positive late-stage readout for VGX later this year.
But until then, investors should probably curb their enthusiasm. Investing Best Accounts. Stock Market Basics. Stock Market. Industries to Invest In. Getting Started.Tokyo Markets Open in:. Inovio Pharmaceuticals, Inc. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; The company was founded by David B. Maxim downgrades Inovio, saying coronavirus opportunity is already 'priced in'. Pfizer Offers Detailed Data on Vaccine.
Dow books best quarter since despite warnings from Powell and Mnuchin on economy. FDA issues rules for coronavirus vaccine developers. Dow closes points lower after spike in coronavirus cases forces Texas and Florida to close bars again, while bank stocks sink on stress tests.
Today p. July 14, How the U. Constitution Is Helping Inovio Pharmaceuticals. Today a. Trump says he has no plans to speak to China's Xi. Ends Preferential Treatment for Hong Kong. Trump signs bill holding China accountable for 'oppressive actions' in Hong Kong. Supreme Court Justice Ginsburg hospitalized for possible infection: reports.
Trump signs order revoking U. Trump says he's signed executive order holding China accountable for Hong Kong actions. Ghislaine Maxwell denied bail after not-guilty plea in Epstein sex-abuse case. Parent company of Calvin Klein, Tommy Hilfiger streamlines operations due to pandemic. All rights reserved. All quotes are in local exchange time. Real-time last sale data for U. Intraday data delayed at least 15 minutes or per exchange requirements. Investor Alert.
Personal Finance.Vaccine development is not an all-or-nothing endeavor. INO can rake in hundreds of millions in revenue if approved, even if only partially successful. Optimistic investors are bidding up shares of both companies, but which one is the better stock pick?
The company has emerged as one of a handful of small drugmakers with promising COVID vaccine candidates. Could buying Inovio stock now make you rich over the next several years?
Yahoo Finance. Sign in. Sign in to view your mail. Finance Home. Inovio Pharmaceuticals, Inc. Currency in USD. Add to watchlist. Summary Company Outlook. Trade prices are not sourced from all markets. Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. Bearish pattern detected. Short-term KST. View all chart patterns. Performance Outlook Short Term. Mid Term. Long Term. Previous Close Volume 42, Market Cap 4. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Research that delivers an independent perspective, consistent methodology and actionable insight. Press Releases. Motley Fool. Experimental Covid vaccine produces antibodies in pc of US trial participants.
Advertise With Us. All rights reserved. Data Disclaimer Help Suggestions. Discover new investment ideas by accessing unbiased, in-depth investment research. Day's Range.Inovio Pharmaceuticals, Inc.
Philly-area company gets $9 million grant to develop vaccine for new Chinese coronavirus
Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens.
Its partners and collaborators include ApolloBio Corp. The company was founded in and is headquartered in Plymouth Meeting, Pennsylvania. Yahoo Finance. Sign in. Sign in to view your mail.
Is Inovio Pharmaceuticals a Screaming Buy?
Currency in USD. Add to watchlist. Summary Company Outlook. Amounts are as of December 31, and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.
Exercised is the value of options exercised during the fiscal year. Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk. Advertise With Us. All rights reserved. Data Disclaimer Help Suggestions.
Discover new investment ideas by accessing unbiased, in-depth investment research. Chief Financial Officer. Jacqueline E. Shea Ph. Chief Operating Officer.Inovio Pharmaceuticals Inc. The newly identified disease, which emerged last month in Wuhan, China, has sickened hundreds and killed at least two dozen, according to Chinese authorities. China on Thursday further cracked down on public transportation out of the city of 11 million. There have been a handful of cases outside of China, including one in the United States, in a man who had recently returned to Washington state from a trip to China.
The U. The company, which is collaborating with the Wistar Institute in Philadelphia, said the grant will be used to support testing of a vaccine against the new virus through phase one trials.
The company also hopes to work in China. Science-based coverage sent each weeknight to your inbox — all facts, no panic. Unlike influenza, coronaviruses do not have a season, Kim said, so an outbreak can continue for years. Coronaviruses are a large family of viruses that can cause respiratory illness in humans and animals. Sometimes these viruses can move from animals to humans and then from person to person.
The newly identified coronavirus, now called nCoV, causes fever, cough, and trouble breathing. An analysis this week from Peking University said it may have spread to people from snakes, who caught it from bats in a food market. It is also spreading among people.
Inovio Pharmaceuticals, Inc. (INO)
Kim said that DNA sequencing of the new virus became publicly available on Jan. David Weiner, a molecular immunologist who is executive vice president of the Wistar Institute and director of its Vaccine Immunotherapy Center, works closely with Inovio and serves on its board.
He said the company grew from the work of his lab, then at the University of Pennsylvania. Scientists identify key proteins on a virus that should make good immune system targets. Then they code pieces of DNA to produce copies of those proteins, mix the DNA in a solution, and inject it into the skin or muscle. For the extra curious, Weiner says DNA is a polymer that looks white and powdery, like salt. Alarmed, it gears up for a fight.
That makes it ready for a quicker, stronger immune response if it ever encounters the full virus. Inovio was founded inKim said. It now has employees and expects to expand with the new grant. This is meant to help the body recognize the parts of viruses that attach to host cells. The amount of that grant was not announced. Until a vaccine is available, he said, leaders are on the right track in trying to prevent exposure to healthy populations.
Weiner said that he sees no reason for Americans to panic about the new virus. So far, we know of only the one case here. Skip to content.
Passengers wear masks to prevent an outbreak of a new coronavirus in the high-speed train station in Hong Kong on Wednesday. The first case of coronavirus in Macao, in a woman who traveled from Wuhan, was confirmed on Wednesday, according to state broadcaster CCTV.
Related stories. The Inquirer Coronavirus Newsletter. Stacey Burling StaceyABurling sburling inquirer. We Recommend.